Singulair (Montelukast) is a Leukotriene inhibitor, used to prevent asthma attacks and to relieve runny nose and sneezing caused by allergies, it was manufactured by Merck, approved for sale in the U.S. in 1998 and has been prescribed to millions of U.S. citizens.

The FDA made an announcement in March 2008 about an ongoing safety review at its center for drug evaluation and research for Motelukast, The agency asked the manufacturer to re-evaluate results of clinical trials following inquiries about a possible link between Singulair use and changes in behavior and mood, suicidality (suicidal thoughts and behavior) and suicide.

In the past year, due to adverse events reported during the post-marketing phase, Merck has updated the patient and prescribing information for Singulair three times to alert doctors and patients of possible side effects such as tremor, depression, suicidal thinking and behavior and anxiousness.

Because of the complexity of the investigation, the FDA has not reached a conclusion about the drug and whether any regulatory action is necessary. Until then, doctors and healthcare professionals should monitor any patients taking Singulair for signs of suicidal thinking and behavior, and any other changes in behavior and mood.

If you or someone you know has taken Singulair and has experienced any of these negative side effects, please contact Goggins & Associates so that we may assist you in winning your case.